Originally posted by El Toro
View Post
The thing to note here is they didn't hit their secondary efficacy endpoint for reducing all infections requiring medical attention (iirc efficacy was around 57% at 3 months, 51% at 6-month follow-up) so we may not see a dramatic change in rates of hospitalizations but definitely a reduction in the worst outcomes.
Given how RSV "season" is going this year, we could use this one ASAP.
Comment